iTind
iTind commercializes a temporarily implanted nitinol device for the minimally invasive treatment of Benign Prostatic Hyperplasia (BPH) in men aged 50+, distributed via trained urologists in outpatient settings under Olympus Corporation of the Americas.
- Company typePrivate
- Founded2007
- HeadquartersOr Akiva, Israel
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What iTind does
iTind is a medical device product line that develops and commercializes a minimally invasive procedure for the treatment of Benign Prostatic Hyperplasia (BPH), a condition affecting approximately 90% of men in their lifetime. The company's flagship product is the iTind device, a temporary implant constructed from nitinol (a nickel-titanium shape memory alloy) that is placed inside the prostate during a brief outpatient procedure. Over 5-7 days, the device expands and applies gentle pressure at key points in the prostatic urethra, creating channels that reduce obstruction and improve urine flow; the device is then completely removed, leaving no permanent implant. The procedure is performed in office or outpatient settings by trained urologists and is positioned as an intermediate option between daily BPH medications and invasive surgery, preserving sexual and urinary function.
iTind received FDA clearance in 2021 and is owned and distributed by Olympus Corporation of the Americas, a subsidiary of Japan's Olympus Corporation, operating as part of Olympus's urology franchise. The company is headquartered in Or Akiva, Israel, with 11-50 employees. Revenue is generated through hardware sales of the disposable nitinol device to urology practices and outpatient clinical settings; pricing is not publicly disclosed. Distribution is sales-led, relying on urologist referrals, a physician finder tool on the company website, and clinical study programs (most notably the MT-08 multicenter randomized trial active at 13 US sites and 3 UK NHS hospitals) to drive physician adoption. Marketing channels include a dedicated consumer website with patient testimonials and educational resources, plus a separate healthcare provider portal at medical.olympusamerica.com.
The company's strategic positioning rests on peer-reviewed clinical evidence (publications in Urology and World Journal of Urology) demonstrating symptom relief durability of over 48 months, fewer than 5% of patients requiring temporary catheter placement, and preservation of sexual function. Operating geographies span North America (US), the United Kingdom, and Germany, with Olympus's Hamburg-based regional headquarters supporting European expansion. iTind does not have independent external investors or public shareholders; it operates as a wholly-owned product line within Olympus's Medical Systems division, with Laborie Medical Technologies noted as a prior strategic investor in 2016.
iTind firmographics
Firmographics- Name
- iTind
- Legal name
- Olympus Corporation of the Americas
- Website
- https://itind.com
- Company type
- Private
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- iTind commercializes a temporarily implanted nitinol device for the minimally invasive treatment of Benign Prostatic Hyperplasia (BPH) in men aged 50+, distributed via trained urologists in outpatient settings under Olympus Corporation of the Americas.
- Ownership category
- akta.pro rank
iTind industry classification
Industry- Product category
- Urology Medical Devices (BPH Treatment)
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Endourology & Minimally Invasive Urologic Surgery (HLAKAOAF)
Keywords
Where iTind is headquartered
LocationHeadquarters
- HQ city
- Or Akiva
- HQ country
- Israel
- HQ region
- Middle East
Offices2 records
Markets served
iTind business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Revenue model
- Medical Device Sales: Revenue is generated from the sale of the iTind temporary implantable nitinol device to healthcare providers and urology practices. The device is used in outpatient procedures performed by trained urologists.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
iTind product offering
Product offeringCore offering
iTind develops, manufactures, and distributes the iTind™ procedure—a minimally invasive treatment for benign prostatic hyperplasia (BPH) that uses a temporary, self-expanding nitinol device implanted in the prostate for 5–7 days to reshape prostatic tissue and improve urine flow. The device is then completely removed, leaving no permanent implant, and is intended for men aged 50 and older who experience lower urinary tract symptoms and want to avoid daily medications or invasive surgery. Revenue is generated through hardware sales of the device to healthcare providers and urology practices performing the outpatient procedure.
Product overview
iTind is a single-product medical device company offering the iTind™ procedure, a minimally invasive treatment for Benign Prostatic Hyperplasia (BPH). The iTind system consists of a temporary implantable nitinol device that is placed inside the prostate during a brief procedure, where it gradually reshapes the prostate over 5-7 days to improve urine flow. The device is then completely removed, leaving no permanent implant. The product is designed for men age 50+ experiencing BPH symptoms who wish to avoid daily medication or invasive surgery while preserving sexual function and urinary continence.
Differentiator
Problem solved
Functional benefit
Products and services
- iTind Procedure A minimally invasive treatment for Benign Prostatic Hyperplasia (BPH) in which a temporary self-expanding nitinol device is implanted in the prostate for 5–7 days to reshape prostatic tissue and improve urine flow, then completely removed leaving no permanent implant. Indicated for men aged 50 and older with lower urinary tract symptoms who seek to avoid daily BPH medication or invasive surgery while preserving sexual and urinary function. The product is sold to healthcare providers and urology practices that perform the procedure in outpatient settings.
Quantifiable outcome
- Most men return to normal activities in days after device removal
- +3 more outcomes
Companies that use iTind
Customer profileNamed customers3 records
Segments2 records
Ideal customer profiles2 records
iTind technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
iTind partnerships and signals
Strategic signalPartnerships
17 partnerships are on record, tiered core and minor.
- Olympus Corporation of the AmericascoreOlympus Corporation of the Americas is the sponsor of the iTind clinical studies and parent company of the iTind product line. The company develops, manufactures, and distributes the iTind temporary implantable nitinol device for BPH treatment.
- Mayo Clinic ArizonaminorClinical study site for the MT-08 BPH treatment clinical trial, participating in the evaluation of the iTind procedure under study physician Mitchell Humphreys.
- Urology Associates of Central California (UACC)minorClinical study site for the MT-08 BPH treatment clinical trial in Fresno, CA, evaluating the iTind procedure under study physician William Schiff.
- Golden State UrologyminorClinical study site for the MT-08 BPH treatment clinical trial in Sacramento/Stockton, CA, evaluating the iTind procedure under study physician Prithipal Sethi.
- Southeast Louisiana Veterans Health Care System (SLVHCS)minorClinical study site for the MT-08 BPH treatment clinical trial in New Orleans, LA, evaluating the iTind procedure in a veteran population.
- Minnesota UrologyminorClinical study site for the MT-08 BPH treatment clinical trial in Woodbury, MN, evaluating the iTind procedure under study physician Spencer Hart.
- Adult & Pediatric UrologyminorClinical study site for the MT-08 BPH treatment clinical trial in Omaha, NE, evaluating the iTind procedure.
- The Feinstein Institutes for Medical Research, Northwell HealthminorClinical study site for the MT-08 BPH treatment clinical trial in Syosset, NY, under study physician Bilal Chughtai.
- Pacific West UrologyminorClinical study site for the MT-08 BPH treatment clinical trial in Las Vegas, NV, evaluating the iTind procedure.
- The Conrad Pearson ClinicminorClinical study site for the MT-08 BPH treatment clinical trial in Germantown, TN, evaluating the iTind procedure.
- Midtown Urology AssociatesminorClinical study site for the MT-08 BPH treatment clinical trial in Austin, TX, evaluating the iTind procedure.
- Houston Metro UrologyminorClinical study site for the MT-08 BPH treatment clinical trial in Houston, TX, evaluating the iTind procedure.
- The Urology PlaceminorClinical study site for the MT-08 BPH treatment clinical trial in San Antonio, TX, under study physician Naveen Kella.
- Potomac Urology CenterminorClinical study site for the MT-08 BPH treatment clinical trial in Alexandria, VA, evaluating the iTind procedure.
- Queen Margaret Hospital (FIFE Health Board)minorUK clinical study site for the MT-08 BPH treatment clinical trial in Dunfermline, UK, under study physician Feras Al Jaafari.
- Frimley Park HospitalminorUK clinical study site for the MT-08 BPH treatment clinical trial in Frimley, UK, under study physician Neil Barber.
- Norfolk & Norwich University HospitalminorUK clinical study site for the MT-08 BPH treatment clinical trial in Norwich, UK, under study physician Mark Rochester.
Scale indicators2 records
Recent moves5 records
Expansion highlights5 records
iTind competitors and assessment
Company assessmentEmerging players
- HistoSonics: HistoSonics is developing histotripsy-based prostate treatments (Edison platform), a non-thermal focused-ultrasound technology. Comparable as an emerging minimally invasive BPH/prostate player with a fundamentally different mechanism targeting the same patient pool.
- AngioDynamics: AngioDynamics markets the NanoKnife system for prostate tissue ablation (irreversible electroporation), an emerging focal therapy approach. Comparable as a newer BPH/prostate intervention technology competing for urologist attention and capital.
Broad incumbents
- Karl Storz: Karl Storz is a major endoscopy and urology device manufacturer serving the same urology surgical workflow that supports iTind procedures. Overlaps with iTind through shared physician relationships and BPH-related capital equipment.
- Richard Wolf: Richard Wolf is a German-founded endoscopy and urology surgical device manufacturer. Comparable as a broad incumbent serving urology procedures with capital equipment that competes for the same physician budget as iTind-related workflows.
- Cook Medical: Cook Medical has a meaningful urology and men's health device portfolio (including BPH-adjacent products). Comparable as a broad incumbent serving the same urology customer base with overlapping procedure-support devices.
- Olympus Corporation: Olympus is iTind's parent and a global leader in urology endoscopy and therapeutic devices. While iTind is its BPH product line, Olympus's broader urology portfolio (resectoscopes, scopes, other therapeutic devices) makes it both a parent and the most directly overlapping incumbent.
Direct peers
- Boston Scientific: Boston Scientific (via acquisition of NxThera) markets the Rezum System, a minimally invasive water-vapor thermal therapy for BPH. Competes head-to-head with iTind for the same outpatient urology BPH patient and the same 'step-up from medication' clinical decision point.
- PROCEPT BioRobotics: PROCEPT BioRobotics markets the Aquablation (AquaBeam) system for BPH using robotic waterjet ablation. Targets the same urologist customer and BPH indication with a technology-forward minimally invasive positioning adjacent to iTind.
- Teleflex: Teleflex (via NeoTract) markets the UroLift System, a leading minimally invasive implant-based BPH treatment. Directly competes with iTind in the same physician call point (urology) and same indication, with a permanent-implant value proposition vs. iTind's temporary approach.
Others
- Laborie Medical Technologies: Laborie is the disclosed prior investor in iTind (2016 funding round) and a broader urology diagnostics and therapeutics company. Comparable as a urology-focused strategic with historical involvement in iTind's commercialization path.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
iTind social profiles
Digital presenceiTind financial estimates
Financial estimateRevenue estimate
Valuation estimate
iTind leadership team
Management profileNumber of profiles
Profiles1 record
iTind funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
iTind M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about iTind
What does iTind do?
iTind develops, manufactures, and distributes the iTind™ procedure—a minimally invasive treatment for benign prostatic hyperplasia (BPH) that uses a temporary, self-expanding nitinol device implanted in the prostate for 5–7 days to reshape prostatic tissue and improve urine flow. The device is then completely removed, leaving no permanent implant, and is intended for men aged 50 and older who experience lower urinary tract symptoms and want to avoid daily medications or invasive surgery. Revenue is generated through hardware sales of the device to healthcare providers and urology practices performing the outpatient procedure.
Is iTind a public or private company?
iTind is a private company. It is classified as corporate owned and is currently operating.
When was iTind founded?
iTind was founded in 2007. It employs 11 to 50 people.
Where is iTind based?
iTind is headquartered in Or Akiva, Israel, in the Middle East region.
How does iTind make money?
One revenue line is on record: medical Device Sales.
Who are iTind's main competitors?
Emerging players on record are HistoSonics and AngioDynamics. Broad incumbents are Karl Storz, Richard Wolf, Cook Medical and Olympus Corporation. Direct peers are Boston Scientific, PROCEPT BioRobotics and Teleflex. Laborie Medical Technologies is listed as an others.
Does iTind have an API?
No public API is recorded for iTind.
What industry is iTind in?
iTind's product category is Urology Medical Devices (BPH Treatment). Its primary akta.pro industry code is HLAKAOAF, Endourology & Minimally Invasive Urologic Surgery. Its NAICS code is 3254 and its SIC code is 3841.